Pasithea Therapeutics' Stunning Reversal: A Deep Dive into the ALS Drug Hopes Fueling a Historic Stock Surge
Eupraxia Pharmaceuticals Secures $70 Million Through Public Offering to Accelerate Osteoarthritis Treatment Development